Sign in
Taking people in United StatesPhase 2

Olatorepatide for hidradenitis suppurativa in adults with overweight or obesity

Tests olatorepatide in adults with hidradenitis suppurativa who live with overweight or obesity.

Key facts

Who runs it
Regeneron Pharmaceuticals
Where
The Bronx, United StatesSee the site
Registry title
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
Status
Recruiting
Phase
Phase 2
People taking part
300 people, planned
Started
29 Oct 2026
Expected to end
22 Dec 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Olatorepatide
  • Placebo
Record updated
10 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe hidradenitis suppurativa (HS) who are also living with overweight or obesity.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
HS for at least 6 months, with lesions in at least 2 different body areas. A total of at least 5 inflammatory lesions (abscesses plus inflammatory nodules) at both the screening and baseline visits.
Earlier treatment
Must agree to use over-the-counter antiseptics on the HS-affected skin every day.
Biomarker or test result
Body mass index (BMI) of at least 27.0 kg/m2 at screening.

Main reasons for not taking part

  • Allergy or past allergic reaction to the trial drug or its parts
  • Heart or brain blood vessel event or procedure in the 90 days before screening
  • Current heart failure of NYHA Class IV
  • Past chronic or acute pancreatitis
  • Type 1 diabetes or any diabetes other than Type 2 diabetes

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Diagnosis of HS based on:; Documented or reported history of HS for ≥6 months prior to baseline visit; Confirmation of HS by the investigator during physical examination at screening
  • HS lesions present in at least 2 distinct anatomic areas as described in the protocol
  • Moderate to severe HS, defined as a total of ≥5 inflammatory lesions (ie, number of abscesses plus number of inflammatory nodules) at both screening (visit 1) and baseline (visit 2)
  • Agree to daily use of over-the-counter topical antiseptics (eg, chlorhexidine gluconate, benzoyl peroxide, or diluted bleach [bath], or alternative antiseptic agents in accordance with local/country guidelines) applied to HS-affected areas as described in the protocol
  • Body Mass Index (BMI) ≥27.0 kg/m2 at screening

Who cannot take part

  • Cardiovascular or cerebrovascular events or procedures within 90 days prior to screening, including myocardial infarction, hospitalization for unstable angina, coronary artery bypass graft, percutaneous coronary intervention as described in the protocol
  • Have a previous or current diagnosis of Type 1 Diabetes (T1D) or any other type of diabetes except Type 2 Diabetes (T2D) as described in the protocol; Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
  • Has a sensitivity (or history of hypersensitivity reactions) to any of the trial interventions, or components thereof, or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the trial
  • Current heart failure classified as being in NYHA Class IV at screening
  • History of chronic pancreatitis or acute pancreatitis
  • Presence of serious Gastrointestinal (GI) disorders (eg, active peptic ulcer, inflammatory bowel disease) at screening

Where in United States

  • Equity Medical, LLCThe Bronx, United StatesContact: Clinical Trials AdministratorTaking people

About the trial

What the trial wants to find out

This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS).

Read full original descriptionShow less

In this study, olatorepatide is being tested in people with HS and living with overweight or obesity to see if it helps improve their HS symptoms and quality of life and helps support weight loss.

The study is looking at:

* What side effects olatorepatide might cause * How well olatorepatide works * How much olatorepatide is in the blood at different times * If the body makes antibodies to olatorepatide, which may cause olatorepatide to not work as well

The 2 groups in the trial

  • OlatorepatideTreatment being tested
  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 52-Week Trial to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
Plain-language title
Olatorepatide for hidradenitis suppurativa in adults with overweight or obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 November 2026